NCT07219849View on ClinicalTrials.gov

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

PHASE2RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

October 17, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
DRUG

ALDP001 Nasal Spray

Experimental Arm

DRUG

Placebo Nasal spray

Controlled arm

Trial Locations (1)

Unknown

RECRUITING

Cliantha Research, Mississauga

Sponsors
All Listed Sponsors
lead

Alixer Nexgen Therapeutics Limited

INDUSTRY

NCT07219849 - A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure | Biotech Hunter | Biotech Hunter